Study S001334

A Phase I/II Proof of Concept, Open-Label, Repeat Dose, Dose Escalation Study of NM-002 in Adult Patients With Short Bowel Syndrome (SBS)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04379856
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1; PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 12
Start: 2020-06-23
Primary completion: 2020-12-11
Lead sponsor: 9 Meters Biopharma, Inc.
Conditions: Short Bowel Syndrome
Interventions: DRUG:NM-002
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

To assess the safety and tolerability of repeated doses of NM002 three different dose levels [56 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.